Auto Parts & Equipment company UNO Minda announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: For the fourth quarter (Q4FY25), revenue rose 19% Y-o-Y to 4,528 crore, up from Rs 3,794 crore in Q4FY24. The EBITDA for Q4FY25 has been reported as Rs 527 crore vis-a-vis Rs 474 crore. in Q4FY24, growth of 11%. PAT (UML Share excluding exceptional income) for Q4FY25 is Rs 266 crore as against Rs 265 crore in Q4FY24, growth of 1%. Uno Minda postea consolidated revenue of Rs 16,775 crore in FY25, a robust increase of 20% compared to Rs14,031 crore in FY24. The EBITDA for the full year grew by 18 % at Rs 1,874 crore. The PAT (UML Share excluding exceptional income) for FY25 was at Rs 936 crore as against~ 855 crore in FY24, growth of 9%. The Board has also approved and declared final dividend of Rs. 1.50 per share i.e. 75% of face value reflecting commitment of the company for returning value to shareholders on consistent basis. FY25 Financial Highlights: Revenue from Operations stood at Rs 16,775 crore vs Rs 14,031 crore in FY24 — up 20% YoY EBITDA stood at Rs 1,874 crore vs Rs 1,585 crore in FY24 — up 18% YoY EBITDA Margin at 11.2% vs 11.3% in FY24 — down 13 bps YoY PAT (UML Share excl. exceptional items) stood at Rs 936 crore vs Rs 855 crore in FY24 — up 9% YoY PAT Margin at 5.6% vs 6.1% in FY24 — down 51 bps YoY EPS (diluted) stood at Rs 16.37 vs Rs 15.24 in FY24 — up 7% YoY Ravi Mehra, Managing Director, Uno Minda Group says; "FY25 has been a defining year for Uno Minda, marked by strategic progress and solid execution. We undertook several high-impact initiatives-including expansion into new product segments like Sunroof, the launch of new ventures like 4W EV products with lnovance Automotive and StarCharge, and the execution of our planned capital expenditure-to strengthen our growth platform. Our commitment to innovation and operational excellence continues to be the cornerstone of our success. We remain confident in our ability to outperform industry growth and create sustained value for all our stakeholders." Sunil Bohra, CFO, Uno Minda Group says, "We continue to deliver strong quarterly and annual performance, with full-year revenue growing by 20%. This growth was broad-based across key segments such as Switches, Lighting, Alloy Wheels, and emerging technologies like Sensors, ADAS, and EV products, and was further supported by the successful commissioning of four major expansion projects. Looking ahead, with around 12 new capacity expansion projects currently underway, we remain confident in sustaining our growth momentum and creating long-term value." Result PDF
Conference Call with Laxmi Organic Industries Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Fortis Healthcare Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Solar Industries India Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Hotels company EIH announced Q4FY25 & FY25 results Consolidated Q4FY25 Financial Highlights: Revenue stood at Rs 866 crore, growing 11% YoY EBITDA rose to Rs 389 crore, an increase of 13% YoY PAT was Rs 262 crore, recording a 6% YoY growth Consolidated FY25 Financial Highlights: Revenue grew to Rs 2,880 crore, up 10% YoY EBITDA was Rs 1,153 crore, a rise of 11% YoY PAT reached Rs 770 crore, increasing 14% YoY Standalone Q4FY25 Financial Highlights: Revenue stood at Rs 757 crore, up 9% YoY EBITDA came in at Rs 336 crore, rising 12% YoY PAT surged to Rs 332 crore, marking a strong 109% YoY growth Standalone FY25 Financial Highlights: Revenue was Rs 2,535 crore, registering a 9% YoY increase EBITDA reached Rs 1,005 crore, up 10% YoY PAT was Rs 751 crore, showing robust growth of 44% YoY Arjun Oberoi, Executive Chairman, The Oberoi Group, commented, This has been a milestone year for EIH Limited, delivering record financial results. Our robust performance reflects our long-term vision, strong governance, and unwavering commitment to excellence. With a solid financial foundation, we are well-positioned to drive strategic growth across key markets while creating sustained value for all our stakeholders.” Vikram Oberoi, CEO, The Oberoi Group, further added, “These results highlight the relentless dedication of our teams and their pursuit of operational excellence. As we continue to expand our footprint, we remain steadfast in delivering exceptional guest experiences driven through our values and culture that places our guests and their wellbeing at the centre of everything we do.” Result PDF
Conference Call with Max Healthcare Institute Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Fortis Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Consolidated Revenues up 12.4% to Rs 2,007 crore Operating EBITDA up 14.3% to Rs 435 crore, 21.7% Margin (vs Q4FY24 at 21.3%) Hospital Business Revenues up 14.2% to Rs 1,701 crore Operating EBITDA up 11.7% to Rs 372 crore, 21.9% Margin (vs Q4FY24 at 22.4%) FY25 Financial Highlights: Consolidated Revenues up 12.9% to Rs 7,783 crore Operating EBITDA up 25.3% to Rs 1,588 crore, 20.4% Margin (vs FY24 at 18.4%) Hospital Business Revenues up 14.8% to Rs 6,528 crore Operating EBITDA up 26.6% to Rs 1,339 crore, 20.5% Margin (vs FY24 at 18.6%) Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed another year of healthy growth and margin improvement. Noticeable developments during the year included the successful acquisition of the ‘Fortis’ brand and trademarks and our foray into Jalandhar with the signing of definitive agreements in February 2025 to acquire the Shrimann Superspecialty Hospital. The transaction enables us to further strengthen our presence in the Punjab region from approximately 800 beds across four facilities to over 1,000 beds. Aligned to our focus on portfolio rationalization, we divested the business operations of Richmond Road Hospital, Bengaluru in December 2024. Given the strength of our balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.” He further added “In FY25, our hospital business contributed 84% to consolidated revenue compared to 82% in FY24. Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16% YoY and contributed 62% to overall hospital business revenues. The Company consolidated its shareholding in Agilus to 89.2% post the acquisition of 31.5% stake from the PE investors. We have witnessed a steady improvement in the diagnostics business EBITDA margins (excluding one-offs) at 22.0% in FY25 compared to 19.6% in FY24. The new brand is being well accepted and gaining prominence; placing the business in a better position to drive business expansion and enhance performance metrics.” Result PDF